Pages

Sunday, 6 January 2019

Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene


Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene



If this proposed acquisition was a game show, it would be called "The Price Isn't Right."

No comments:

Post a Comment